UVADEX Drug Patent Profile

When do Uvadex patents expire, and what generic alternatives are available?

Uvadex is a drug marketed by Therakos Development and is included in one NDA.

The generic ingredient in UVADEX is methoxsalen. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methoxsalen profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Uvadex

A generic version of UVADEX was approved as methoxsalen by ONESOURCE SPECIALTY on June 5^th, 2014.

Summary for UVADEX

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	18
Patent Applications:	5,458
Drug Prices:	Drug price information for UVADEX
What excipients (inactive ingredients) are in UVADEX?	UVADEX excipients list
DailyMed Link:	UVADEX at DailyMed

See drug prices for UVADEX

Recent Clinical Trials for UVADEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Therakos LLC	PHASE2
Central Hospital, Nancy, France	Phase 2
Lawson Health Research Institute	Phase 2

See all UVADEX clinical trials

Pharmacology for UVADEX

Drug Class	Photoactivated Radical Generator Psoralen
Mechanism of Action	Photoabsorption
Physiological Effect	Photosensitizing Activity

US Patents and Regulatory Information for UVADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Therakos Development	UVADEX	methoxsalen	INJECTABLE;INJECTION	020969-001	Feb 25, 1999		RX	Yes	Yes

Expired US Patents for UVADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Therakos Development	UVADEX	methoxsalen	INJECTABLE;INJECTION	020969-001	Feb 25, 1999
Therakos Development	UVADEX	methoxsalen	INJECTABLE;INJECTION	020969-001	Feb 25, 1999
Therakos Development	UVADEX	methoxsalen	INJECTABLE;INJECTION	020969-001	Feb 25, 1999

International Patents for UVADEX

See the table below for patents covering UVADEX around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0392429	PSORALEN-REAGENS
Germany	487116
Germany	3588218
Netherlands	990016

Supplementary Protection Certificates for UVADEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0177957	SPC/GB99/023	United Kingdom		PRODUCT NAME: BECAPLERMIN; REGISTERED: UK EU/1/99/101/001 19990329
0177957	C990016	Netherlands		PRODUCT NAME: BECAPLERMINUM; REGISTRATION NO/DATE: EU/1/99/101/001 19990329
0177957	99C0034	Belgium		PRODUCT NAME: BECAPLERMIN; REGISTRATION NO/DATE: EU/1/99/101/001 19990329

UVADEX Market Analysis and Financial Projection

Last updated: February 14, 2026

UVADEX (amphotericin B lipid complex) is primarily used as an antifungal agent for invasive fungal infections, including aspergillosis and cryptococcal meningitis, especially in immunocompromised patients. The drug's market dynamics and financial trajectory are influenced by several factors, including efficacy, competition, regulatory environment, and healthcare trends.

Market Size and Demand Drivers

The global antifungal drugs market was valued at approximately $10 billion in 2022, with UVADEX accounting for a niche segment due to its specialized usage. The rising incidence of invasive fungal infections, particularly among patients undergoing hematopoietic stem cell or solid organ transplants, HIV/AIDS, and cancer therapies, fuels demand for amphotericin B formulations.

The increased focus on managing immunocompromised states and rising global transplant procedures are driving incremental growth. Estimated annual growth rates (CAGR) for the antifungal segment range between 4% and 6% (Source: MarketsandMarkets).

Regulatory and Patent Landscape

UVADEX was originally developed by GlaxoSmithKline (GSK), which maintained market exclusivity via patents until their expiration in up to 2020s, depending on jurisdiction. Patent expiry opens the market to biosimilars or generic formulations, exerting pricing pressures.

Recent regulatory actions may include approvals for generic versions, contingent on local patent challenges, which could lower healthcare costs but dilute revenue streams for originators.

Competitive Environment

UVADEX competes with other amphotericin B formulations, including amphotericin B deoxycholate (conventional), liposomal amphotericin B (Ambisome), and other lipid-based complexes. Liposomal formulations typically command premium pricing—up to 20-25% higher than amphotericin B lipid complexes—due to improved safety profiles.

New players and generics threaten market share, especially in cost-sensitive emerging markets. Competing drugs like isavuconazole and posaconazole are expanding options, targeting similar indications with oral formulations that offer convenience.

Pricing Trends

Pricing for UVADEX and its competitors has seen pressure driven by patent expiries and increased generic availability. Still, high manufacturing costs and the need for specialized administration may sustain higher prices relative to traditional formulations.

In established markets (U.S., Europe), prices for patented formulations range from $300 to $1,000 per infusion, with biosimilars reducing prices by approximately 15-30%. In developing nations, prices are often 40-60% lower, impacting profit margins.

Revenue and Financial Forecasts

Revenue projections for UVADEX depend on:

• Market penetration in hospitals treating immunocompromised patients.
• Adoption rates influenced by clinical guidelines favoring less toxic formulations.
• Competitive pressure from biosimilars and generics.

Analysts estimate that original brand sales decline at 10-15% annually post-patent expiry, while generic markets expand, potentially leading to a 20-30% reduction in pricing and revenue within 3-5 years after patent loss.

For instance, if GSK or successor companies generated $150 million annually pre-patent expiry, this could decline to approximately $100 million or less within five years, unless the drug maintains market dominance through clinical differentiation.

Emerging Trends Impacting Financial Trajectory

• Development of new antifungal agents with better safety profiles, such as extended-spectrum azoles.
• Adoption of combination therapies reducing reliance on amphotericin B.
• Shifts towards oral administration options improving outpatient treatment prospects.

In vaccine and immunotherapy sectors, increased emphasis on prophylactic strategies could otherwise limit the use of heavy antifungal treatments, impacting long-term revenue.

Key Risks and Opportunities

Risks include patent challenges, pricing pressures, and clinical preference shifts. Opportunities emerge from niche indications where UVADEX’s safety and efficacy are superior, and regional expansion into emerging markets where fungal infections are more prevalent but cost constraints favor generics.

Summary

UVADEX's market remains stable in specialized niches but faces declining revenues over the next five years due to patent expiries, generics, and competitive drugs. Growth hinges on maintaining clinical relevance, expanding indications, and geographic expansion.

---

Key Takeaways

• UVADEX operates in a specialized antifungal segment with limited but steady demand.
• Patent rights expiration significantly impacts revenue, with potential declines of 20-30% within five years.
• Competition from biosimilars, generics, and newer antifungals constrains pricing power.
• Growth opportunities exist in emerging markets and niche indications where safety advantages are clear.
• Industry shifts towards oral formulations and prophylactic strategies could reduce demand.

---

FAQs

1. How does UVADEX compare to other amphotericin B formulations?
UVADEX has a lipid complex that reduces toxicity compared to conventional amphotericin B deoxycholate. Liposomal formulations offer similar safety advantages but at higher costs. Pricing depends on formulation type, with generics pushing prices downward.

2. What factors influence UVADEX’s patent expiration?
Patent expiration depends on jurisdiction and specific patents covering formulation or manufacturing processes. The original patents expired or are nearing expiry in key markets, increasing generic competition.

3. How does the rise of azole antifungals impact UVADEX?
Azoles, especially orally available drugs like isavuconazole, compete with amphotericin B for invasive fungal infection treatment. They offer easier administration and fewer side effects but may not be suitable for all patient populations.

4. What regional markets offer growth potential for UVADEX?
Emerging markets with high fungal infection rates, such as parts of Asia, Africa, and Latin America, present expansion opportunities. Cost sensitivity favors generic formulations once patent protections lapse.

5. How might future innovations affect UVADEX’s market?
Development of safer, more effective antifungal therapies and prophylactic strategies could diminish UVADEX’s market share. Conversely, new formulations with improved safety could sustain demand among specific patient groups.

---

References

[1] MarketsandMarkets, "Antifungal Drugs Market by Region, Type, & Distribution Channel," 2022.